Troriluzole for Obsessive-Compulsive Disorder
This trial is testing if a new drug, troriluzole, is better than placebo at treating OCD when used with current OCD treatments.
- Obsessive-Compulsive Disorder
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Other reimbursement is provided
Other forms of reimbursement are provided for this trial.
Who is running the clinical trial?
Frequently Asked Questions
Has the Federal Drug Administration cleared Troriluzole for public use?
"There is some evidence of efficacy and extensive safety data available from Phase 3 trials, so we have rated Troriluzole as a 3."
If I'm younger than 70, can I still participate in this research?
"The age bracket for potential recruits begins at 18 years old and ends at 65."
Have other research groups attempted anything similar to this project?
"Troriluzole is being studied in 6 active clinical trials across 8 countries and 161 cities. The first trial for Troriluzole was completed in 2016 by Biohaven Pharmaceuticals, Inc. That particular study involved 141 patients and completed Phase 2 & 3 of drug approval. Since then, 18279 more trials have been conducted."
Are there any other research studies that have used Troriluzole?
"The first clinical trial for troriluzole was completed in 2016 at the University of Rochester Medical Center. Currently, there have been a total of 18279 studies. There are 6 trials that are still recruiting patients, with several locations in Dayton, Ohio."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- WR-PRI, LLC (Encino): < 24 hours
Average response time
- < 1 Day